GenMont Biotech, Inc. Statistics
GenMont Biotech, Inc. (3164) Stock Statistics & Valuation Metrics
Total Valuation
GenMont Biotech, Inc. has a market cap or net worth of TWD 1.43B. The enterprise value is TWD 1.20B.
- Market Cap
- TWD 1.43B
- Enterprise Value
- TWD 1.20B
Share Statistics
GenMont Biotech, Inc. has 86,010,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 86,010,360
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
GenMont Biotech, Inc.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 2.78%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 2.78%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 2.73M
- Profits Per Employee
- 389.10K
- Employee Count
- 147
- Asset Turnover
- 0.24
- Inventory Turnover
- 2.13
Valuation Ratios
The current PE Ratio of GenMont Biotech, Inc. is 20.56. GenMont Biotech, Inc.’s PEG ratio is 0.06.
- PE Ratio
- 20.56
- PS Ratio
- 3.75
- PB Ratio
- 1.10
- Price to FCF
- 16.79
- Price to Operating Cash Flow
- 16.60
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, GenMont Biotech, Inc. had revenue of 401.23M and earned 57.20M in profits. Earnings per share was 0.66.
- Revenue
- 401.23M
- Gross Profit
- 251.63M
- Operating Income
- 57.75M
- Pretax Income
- 63.68M
- Net Income
- 57.20M
- EBITDA
- 124.57M
- Earnings Per Share (EPS)
- 0.66
Cash Flow
In the last 12 months, operating cash flow was 86.59M and capital expenditures -1.31M, giving a free cash flow of 85.27M billion.
- Operating Cash Flow
- 86.59M
- Free Cash Flow
- 85.27M
- Free Cash Flow per Share
- 0.99
Dividends & Yields
GenMont Biotech, Inc. pays an annual dividend of ―, resulting in a dividend yield of 4.80%
- Dividend Per Share
- ―
- Dividend Yield
- 4.80%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.95%
- Earnings Yield
- 4.81%
Stock Price Statistics
- Beta
- 0.16
- 52-Week Price Change
- -10.00%
- 50-Day Moving Average
- 16.46
- 200-Day Moving Average
- 16.78
- Relative Strength Index (RSI)
- 47.48
- Average Volume (3m)
- 37.09K
Important Dates
GenMont Biotech, Inc. upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
GenMont Biotech, Inc. as a current ratio of 4.28, with Debt / Equity ratio of 8.29%
- Current Ratio
- 4.28
- Quick Ratio
- 3.74
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.05
- Interest Coverage Ratio
- 14.75
Taxes
In the past 12 months, GenMont Biotech, Inc. has paid 15.70M in taxes.
- Income Tax
- 15.70M
- Effective Tax Rate
- 0.25
Enterprise Valuation
GenMont Biotech, Inc. EV to EBITDA ratio is 12.47, with an EV/FCF ratio of 17.07.
- EV to Sales
- 3.81
- EV to EBITDA
- 12.47
- EV to Free Cash Flow
- 17.07
- EV to Operating Cash Flow
- 16.81
Balance Sheet
GenMont Biotech, Inc. has TWD 354.63M in cash and marketable securities with TWD 125.85M in debt, giving a net cash position of TWD 228.78M billion.
- Cash & Marketable Securities
- TWD 354.63M
- Total Debt
- TWD 125.85M
- Net Cash
- TWD 228.78M
- Net Cash Per Share
- TWD 2.66
- Tangible Book Value Per Share
- TWD 16.53
Margins
Gross margin is 59.54%, with operating margin of 7.00%, and net profit margin of 18.10%.
- Gross Margin
- 59.54%
- Operating Margin
- 7.00%
- Pretax Margin
- 21.22%
- Net Profit Margin
- 18.10%
- EBITDA Margin
- 30.54%
- EBIT Margin
- 12.80%
Analyst Forecast
The average price target for GenMont Biotech, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -1.11%
- EPS Growth Forecast
- 347.16%
